Tata Institute develops Rs 100 tablet which stops cancer recurrence
The tablet developed by Tata Memorial Centre (TMC) for preventing cancer recurrence is a significant breakthrough in cancer research and treatment. It offers a potentially affordable solution to a critical aspect of cancer management. However, its availability to the public hinges on the approval process from the Food Safety and Standards Authority of India (FSSAI).
According to the information provided, the tablet is currently awaiting approval from FSSAI. The scientists from Tata Institute of Fundamental Research (TIFR) have applied for approval, indicating a proactive step towards making the tablet accessible to the public. Once FSSAI grants approval, the tablet is expected to be available in the market by June-July.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd